{
     "PMID": "15225720",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20050412",
     "LR": "20131121",
     "IS": "0960-894X (Print) 0960-894X (Linking)",
     "VI": "14",
     "IP": "15",
     "DP": "2004 Aug 2",
     "TI": "The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors.",
     "PG": "4027-30",
     "AB": "Elevation of glycine levels and activation of the NMDA receptor by inhibition of the glycine transporter 1 (GlyT-1) is a potential strategy for the treatment of schizophrenia. A novel series of GlyT-1 inhibitors have been identified containing the 2-arylsulfanyl-phenylpiperazine motif. The most prominent member of this series, (R)-4-[5-chloro-2-(4-methoxy-phenylsulfanyl)-phenyl]-2-methyl-piperazin-1-yl-acet ic acid (31) is a potent glycine transporter-1 inhibitor (IC(50)=150 nM), which elevated glycine levels in rat ventral hippocampus as measured by microdialysis in vivo at doses of 1.2-4.6 mg/kg s.c.",
     "FAU": [
          "Smith, Garrick",
          "Ruhland, Thomas",
          "Mikkelsen, Gitte",
          "Andersen, Kim",
          "Christoffersen, Claus Tornby",
          "Alifrangis, Lene Hjorth",
          "Mork, Arne",
          "Wren, Stephen P",
          "Harris, Neil",
          "Wyman, Barry M",
          "Brandt, Guillaume"
     ],
     "AU": [
          "Smith G",
          "Ruhland T",
          "Mikkelsen G",
          "Andersen K",
          "Christoffersen CT",
          "Alifrangis LH",
          "Mork A",
          "Wren SP",
          "Harris N",
          "Wyman BM",
          "Brandt G"
     ],
     "AD": "Medicinal Chemistry Research, H. Lundbeck A/S, 9 Ottiliavej, DK 2500 Valby, Denmark. gsm@lundbeck.com",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "PL": "England",
     "TA": "Bioorg Med Chem Lett",
     "JT": "Bioorganic & medicinal chemistry letters",
     "JID": "9107377",
     "RN": [
          "0 (Acetates)",
          "0 (Amino Acid Transport Systems, Neutral)",
          "0 (Antipsychotic Agents)",
          "0 (Glycine Plasma Membrane Transport Proteins)",
          "0 (Piperazines)",
          "0 (Receptors, N-Methyl-D-Aspartate)",
          "0 (SLC6A9 protein, human)",
          "0 (Slc6a9 protein, rat)",
          "TE7660XO1C (Glycine)"
     ],
     "SB": "IM",
     "MH": [
          "Acetates/chemical synthesis/chemistry/pharmacology",
          "Amino Acid Transport Systems, Neutral/*antagonists & inhibitors",
          "Animals",
          "Antipsychotic Agents/*chemical synthesis/therapeutic use",
          "Glycine/metabolism",
          "Glycine Plasma Membrane Transport Proteins",
          "Hippocampus/drug effects/metabolism",
          "Humans",
          "Kinetics",
          "Models, Molecular",
          "Molecular Conformation",
          "Molecular Structure",
          "Piperazines/*chemical synthesis/chemistry/*pharmacology",
          "Rats",
          "Receptors, N-Methyl-D-Aspartate/drug effects",
          "Schizophrenia/drug therapy",
          "Structure-Activity Relationship"
     ],
     "EDAT": "2004/07/01 05:00",
     "MHDA": "2005/04/13 09:00",
     "CRDT": [
          "2004/07/01 05:00"
     ],
     "PHST": [
          "2004/03/08 00:00 [received]",
          "2004/04/28 00:00 [revised]",
          "2004/05/18 00:00 [accepted]",
          "2004/07/01 05:00 [pubmed]",
          "2005/04/13 09:00 [medline]",
          "2004/07/01 05:00 [entrez]"
     ],
     "AID": [
          "10.1016/j.bmcl.2004.05.043 [doi]",
          "S0960894X04006948 [pii]"
     ],
     "PST": "ppublish",
     "SO": "Bioorg Med Chem Lett. 2004 Aug 2;14(15):4027-30. doi: 10.1016/j.bmcl.2004.05.043.",
     "term": "hippocampus"
}